Viking Therapeutics (VKTX) Starts Presentation at LD Micro Main Event
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company that focuses on the development of therapies for metabolic and endocrine disorders. The company's lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. Viking is also developing VK5211, an orally available drug candidate, which is in a Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. For more information, visit the company's website at www.vikingtherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial…







